Imugene (ASX: IMU) is buying Biolife Science Qld Ltd., granting it access to new forms of cancer treatments.

Brisbane, Australia-based Biolife currently owns the rights to a cancer immunotherapy developed by scientists at the University Medical School in Austria. The medication aims to produces an antibody response against tumors, including breast cancer and gastric cancer. Reports indicate the medication, if it gets approval, would be less expensive than other methods of cancer treatment.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.